Sfoglia per AUTORE
FABI A
Collezione AO Cuneo

  

Items : 12

Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2023 Aug;189:112920. doi: 10.1016/j.ejca.2023.05.008. Epub 2023 May 15.

2023
AO Cuneo
ASL Cuneo 2
AO Ordine Mauriziano
ASL Torino 4
AOU San Luigi di Orbassano

Tuninetti V; Turco F; Fabi A; Perrone F; Di Maio M; Reale ML; Trastu F; Paratore C; Marandino L; Mariniello A; Lombardi P; Ghisoni E; Bungaro M; Caglio A; Di Liello R; Gamba T; Gargiulo P; Rossi A; Aimar G; Audisio M;

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10.

2022
AO Cuneo
ASL Città di Torino

Lambertini M; Colantuoni G; Puglisi F; Montemurro F; Bighin C; Correale P; Poletti P; Mansutti M; Alicicco MG; Urracci Y; Gasparro S; Garrone O; Fabi A; Cognetti F; Vaccaro A; Nisticò C; Turletti A; Bisagni G; Rimanti A; Gravina A; De Laurentiis M; Forestieri V; Giuliano M; Blondeaux E; De Placido S; Poggio F; Boni L; Del Mastro L;

Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial. in Frontiers in oncology / Front Oncol. 2022 Sep 15;12:925366. doi: 10.3389/fonc.2022.925366. eCollection 2022.

2022
AO Ordine Mauriziano
AO Cuneo
ASL Cuneo 1
AOU Alessandria

Mariani G; Di Pede P; Spinelli GP; Santini D; Zustovich F; Bossi P; Di Maio M; Numico G; Gunnellini M; Rossi M; Giordano M; Corsi DC; Fabi A; Berruti A; Coletta D; Sbrana A; Galli L; Miccinesi G; Velutti L; Sammarco E; Roila F; Antonuzzo A; Ripamonti CI;

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Oct;22(10):1458-1467. doi: 10.1016/S1470-2045(21)00352-1. Epub 2021 Sep 17.

2021
AO Cuneo
AOU Città della Salute di Torino

Bruzzi P; Montemurro F; Ballestrero A; Lambertini M; Amaducci L; Campadelli E; Arpino G; Moretti G; Tamberi S; Bighin C; Puglisi F; Barone C; Garrone O; Fabi A; Gori S; De Placido S; Urracci Y; Sanna G; Mura S; Michelotti A; Poggio F; Frassoldati A; Cognetti F; Durando A; Ponzone R; Del Mastro L; Mansutti M; Bisagni G;

Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. in International journal of cancer / Int J Cancer. 2020 Jul 1;147(1):160-169. doi: 10.1002/ijc.32789. Epub 2019 Dec 4.

2020
ASL Città di Torino
AO Cuneo
AOU Città della Salute di Torino

Del Mastro L; Ceppi M; Montemurro F; Puglisi F; Garrone O; Fabi A; Bisagni G; Durando A; Turletti A; Urracci Y; Cognetti F; De Laurentiis M; Giuliano M; Bighin C; de Azambuja E; Conte B; Poggio F; Bruzzone M; Lambertini M;

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. in Breast care (Basel, Switzerland) / Breast Care (Basel). 2020 Feb;15(1):30-37. doi: 10.1159/000495469. Epub 2019 Apr 17.

2020
AO Cuneo

Mustacchi G; Pronzato P; Torri V; Marchetti P; Montemurro F; Riccardi F; Romagnoli E; Bisagni G; Livi L; Natoli C; Donadio M; Biganzoli L; Del Mastro L; Clivio L; Giordano M; Frassoldati A; Scavelli C; Ferzi A; Schirone A; Palumbo R; Gebbia V; Fabi A; Santini D; Turletti A; Porpiglia M; Atzori F; Blasi L; De Laurentiis M; Artale S; et alii...

The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. in Clinical breast cancer / Clin Breast Cancer. 2019 Aug;19(4):e501-e510. doi: 10.1016/j.clbc.2019.05.006. Epub 2019 May 18.

2019
AO Cuneo

Valerio M; Marchetti F; Russo A; Barni S; Galanti D; Leonardi V; Cavanna L; Foglietta J; Turazza M; Cretella E; Laudadio L; Vici P; Garrone O; Tarenzi E; Frassoldati A; La Verde N; Fabi A; Moroso S; Gori S; Puglisi F; Lunardi G; Alongi F; Inno A;

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.

2018
ASL Città di Torino
AO Cuneo

Clivio L; Torri On Behalf Of The Eva Study Group V; Frassoldati A; Scavelli C; Palumbo R; Ferzi A; Schirone A; Cursano MC; Fabi A; Gebbia V; Benedetto C; Atzori F; Turletti A; Blasi L; Piezzo M; Artale S; Mentuccia L; La Verde N; Bianchi G; Musolino A; Vici P; Maur M; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

2018
ASL Città di Torino
AO Cuneo

Torri V; Frassoldati A; Clivio L; Scavelli C; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Benedetto C; Cursano MC; Turletti A; Atzori F; Artale S; Blasi L; Piezzo M; Bianchi G; Maur M; La Verde N; Mentuccia L; Vici P; Musolino A; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7.

2018
ASL Città di Torino
AO Cuneo

Torri On Behalf Of The Eva Study Group V; Clivio L; Scavelli C; Frassoldati A; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Cursano MC; Turletti A; Benedetto C; Atzori F; Piezzo M; Artale S; Blasi L; La Verde N; Bianchi G; Maur M; Mentuccia L; Vici P; Musolino A; Garrone O; Pistelli M; Zambelli A; Febbraro A; Generali D; Diodati L; Arcangeli V; et alii...

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. in Breast (Edinburgh, Scotland) / Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.

2017
AO Cuneo
ASL Città di Torino

Clivio L; Zambelli A; Blasi L; Torri V; Sartori D; Scavelli C; Schirone A; Turletti A; Vici P; Valerio MR; Palumbo R; Pistelli M; Musolino A; Porpiglia M; Arcangeli V; Artale S; Atzori F; Ballerio A; Bianchi GV; Moretti G; Maur M; Michelotti A; La Verde N; Generali D; Gebbia V; Garrone O; Fumagalli A; Frassoldati A; Ficorella C; et alii...

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. in PloS one / PLoS One. 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. eCollection 2015.

2015
ASL Cuneo 1
AO Cuneo
AOU Novara

Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L; Gamucci T; Evangelisti L; Barni S; Saracchini S; Amaducci L; Santini D; Fabi A; Garrone O; Frassoldati A; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Spazzapan S; Iezzi L; De Simone V; Duranti S; Cavazzini MG; Turazza M; Gubiotti M; Foglietta J; et alii...